Exhibits and Industry Support
During The Liver Meeting Digital Experience™ (TLMdX), hepatologists and hepatology health professionals from across the nation and around the world will experience The Liver Meeting® in a new and exciting way on November 13-16, 2020. Liver disease research, treatment outcome discussions, and interaction among colleagues will all take place during this must-attend event. AASLD continues to be the leading organization focused solely on advancing the science and practice of hepatology and defines the cutting edge in the study and treatment of liver and biliary diseases and offers a premiere environment to discuss groundbreaking research and progressive clinical treatments.
TLMdX™ will be held on Freeman’s state-of-the-art virtual event platform. Exhibitors and Corporate Supporters will have countless options to customize their booths, and banner advertisements with their marketing materials, along with additional support events and opportunities. Each option allows your organization to directly connect and interact with conference attendees.
Unlike in-person events, TLMdX can track participant engagement through online tools. You can assess return on investment by tracking the reach of your content, identifying who engaged, and accessing emails to follow up after the conference.
Download our Prospectus and Application and Contract.
Satellite Symposia
AASLD offers commercial supporters of The Liver Meeting Digital Experience the opportunity to organize a limited number of independent educational symposia to be presented during TLMdX for registered participants. These symposia will take place at designated times following scheduled educational events of TLMdX and are designed to meet the continuing medical education needs of the hepatology community.
Unraveling the Intricacies of HCC Management With Your Multidisciplinary Team: A Closer Look at Effective Selection and Sequencing Strategies in an Expanding Treatment Landscape
7:00 PM-8:30 PM, Friday, November 13, 2020
Supported by: AstraZeneca, Bristol Myers Squibb, Exelixis, Inc., Merck & Co., and Novocure
Organized by: PVI, PeerView Institute for Medical Education
CME provided by: Medical Learning Institute, Inc.
On completion of this activity, participants should be able to:
- Review the key clinical evidence on available systemic treatments, including multikinase, immune checkpoint, and anti-angiogenic inhibitors, for advanced HCC
- Assess available and emerging combination strategies, such as targeted therapies with immunotherapy, dual checkpoint inhibition, and systemic agents with locoregional modalities, across the disease spectrum of HCC
- Develop personalized therapeutic plans in the first and subsequent lines of treatment for patients with advanced HCC
- Incorporate multidisciplinary care approaches for the optimal management of patients with HCC, including those along the intermediate-to-advanced stage disease continuum
For more information, contact the PeerView Live team at 1-877-833-6141, email live@PeerView.com, or visit PeerView.com/HCC20-Live.
Applying Advances in HRS Management
7:00 PM-8:30 PM, Saturday, November 14, 2020
Supported by: Mallinckrodt
Organized by: Medscape Education
CME provided by: Medscape, LLC
On completion of this activity, participants should be able to:
Increased knowledge regarding:
- New/emerging treatment approaches for HRS
- Safety and efficacy data for new/emerging treatment options for HRS
- Updates to guideline recommendations for diagnosis and treatment of HRS
Greater competence related to:
- Early recognition and diagnosis of patients with HRS
- Modern, evidence-based treatment strategies for patients with HRS
For more information, contact Olalla Barcelo at obarcelo@medscapelive.com or www.medscape.org/symposium/advances-hrs-management.
Stronger Together: An Emerging Era of Combination Regimens for Unresectable HCC
7:00 PM-8:00 PM, Saturday, November 14, 2020
Supported by: Eisai Inc., Exelixis, Inc., Genentech, a member of the Roche Group, and Merck Sharp & Dohme Corp.
Organized by: RMEI Medical Education, LLC
CME provided by: Advancing Knowledge in Healthcare (AKH)
On completion of this activity, participants should be able to:
- Develop treatment plans for patients with advanced hepatocellular carcinoma (HCC) that integrate checkpoint inhibitors and targeted synthetic agents based on their efficacy and safety data
- Develop individualized treatment plans for patients with advanced HCC across multiple lines of therapy
- Analyze the safety and efficacy of new and emerging combination regimens for HCC
Register online at www.RMEI.com/HCC2020.
Potential Therapeutic Roles for IBAT Inhibitors in Cholestatic and Metabolic Liver Diseases
7:00 PM-9:00 PM, Sunday, November 15, 2020
Supported by: Albireo Pharmaceuticals
Organized by: Liberum IME
CME provided by: ACHL
On completion of this activity, participants should be able to:
- Describe the pathophysiological features of cholestatic and metabolic liver diseases, as well as clinical outcomes associated with these conditions
- Discuss the mechanism of action of ileal bile acid transporter (IBAT) inhibitors and their proposed effects on cholestatic liver disease and metabolic disease
- Recall clinical trial data regarding the efficacy and safety of IBAT inhibitors in the treatment of cholestatic liver disease, including biliary atresia and progressive familial intrahepatic cholestasis (PFIC)
- Identify potential future clinical applications for the IBAT inhibitor class in hepatic and metabolic diseases
For more information please contact Mia Neve at mia.neve@liberumime.com or visit http://bit.ly/symposium-IBAT-register.
Product Theaters
Product Theaters are 30-minute marketing presentations about your company’s products or services. These sessions do not offer CME credit; rather, they give exhibitors the freedom to create a presentation centered on their company’s products and/or services.
Management of Overt Hepatic Encephalopathy in an Expanding Population of Patients with Cirrhosis; Considerations for a COVID-19 Environment
1:00 PM-1:30 PM Friday, November 13, 2020
Supported by: Salix Pharmaceuticals │ Presented by: Arun Jesudian, MD
Salix Pharmaceuticals invites you to explore Management of Overt Hepatic Encephalopathy in an Expanding Population of Patients with Cirrhosis; Considerations for a COVID-19 Environment, a non-CME virtual product theater presented by Dr. Arun Jesudian.
Resmetirom for the Treatment of NASH: Early Data from the Phase 3 MAESTRO Clinical Trials
4:30 PM-5:00 PM, Friday, November 13, 2020
Supported by: Madrigal Pharmaceuticals │ Presented by: Stephen A. Harrison, MD
Resmetirom is an investigational drug currently being evaluated for the treatment of NASH with fibrosis in two Phase 3 studies: MAESTRO-NASH (NCT03900429) and MAESTRO-NAFLD-1 (NCT04197479). Stephen Harrison, MD will discuss data from the open label arm of MAESTRO-NAFLD-1 and a screening algorithm for predicting NASH with fibrosis on liver biopsy in MAESTRONASH.
LENVIMA® Monotherapy as First-Line Treatment Option for Patients with Unresectable Hepatocellular Carcinoma
1:00 PM-1:30 PM, Saturday, November 14, 2020
Supported by: Eisai Inc. │ Presented by: Catherine Frenette, MD
Objectives:
- Evaluate the efficacy and safety from the REFLECT trial that supports the use of LENVIMA as a first-line treatment option in patients with unresectable HCC (uHCC)
- Review patient case with uHCC to highlight potential treatment outcomes and adverse event management strategies associated with LENVIMA
Clinical Management of HCC With CABOMETYX®
1:30 PM-2:00 PM, Saturday, November 14, 2020
Supported by: Exelixis Inc │ Presented by: Catherine Frenette, MD
Exelixis Access Services® (EASE) provides a variety of support to help your patients get started on treatment as soon as possible. EASE can help meet the unique needs of your patients and practice at each step along the access journey.
Biomarkers in Liver Transplantation: The Next Frontier
1:00 PM-1:30 PM, Sunday, November 15, 2020
Supported by: Eurofins - Transplant Genomics │ Presented by: Josh Levitsky, MD
Dr. Levitsky will share how a blood-based biomarker can be used for detecting rejection in liver transplant recipients.
CME provided by: Medical Learning Institute, Inc.
Session 1: Seeking a Cure for Chronic Hepatitis B: The Need, The Mechanisms and The Treatment Goals
4:30 PM-5:00 PM, Sunday, November 15, 2020
Supported by: GlaxoSmithKline │ Presented by: Nezam Afdhal, Chari Cohen, Harry Janssen
Chronic Hepatitis B is the most common chronic viral infection worldwide, and is a leading cause of liver-related morbidity and mortality, alongside reduced quality of life and social stigma. In this webinar, we will discuss current treatment approaches and the potential for functional cure with new therapies under investigation.
Session 2: Seeking a Cure for Chronic Hepatitis B: The Need, The Mechanisms and The Treatment Goals – Audience Q&A
5:00 PM -5:30 PM, Sunday, November 15, 2020
Supported by: GlaxoSmithKline │ Presented by: Nezam Afdhal, Chari Cohen, Harry Janssen
Chronic Hepatitis B is the most common chronic viral infection worldwide, and is a leading cause of liver-related morbidity and mortality, alongside reduced quality of life and social stigma. In this webinar, we will discuss current treatment approaches and the potential for functional cure with new therapies under investigation.
Advancement in the 1L Treatment of Unresectable and Metastatic HCC A Review of the IMbrave150 Trial
5:00 PM-5:30 PM, Sunday, November 15, 2020
Supported by: Genentech │ Presented by: Catherine Frenette, MD
Objectives:
- Hepatocellular carcinoma disease and staging
- The IMbrave150 clinical trial design, patient characteristics, efficacy, and safety data
- Genentech patient support information
